Skip to main content

Table 6 Types of immunosuppressants of flare and non-flare group in SACQ and SQCQ patients

From: Treatments and outcomes in Chinese patients with serologically active clinically quiescent systemic lupus erythematosus: a retrospective observational study

  SACQ (170) SQCQ (187)
Flare (23/56) Non-flare (69/114) p Flare (10/29) Non-flare (87/158) p
AZA 12/23 (52.5%) 27/69 (39.1%) 0.273 2/10 (20%) 23/87 (26.4%) 0.659
MMF 5/23 (21.7%) 23/69 (33.3%) 0.295 1/10 (10%) 21/87 (24.1%) 0.540
MTX 3/23 (13.0%) 11/69 (15.9%) 1.000 6/10 (60%) 23/87 (26.4%) 0.067
LEF 2/23 (8.7%) 8/69 (11.6%) 1.000 5/10 (50%) 20/87 (23.0%) 0.142
CTX 3/23 (13.0%) 4/69 (5.8%) 0.496 2/10 (20%) 6/87 (6.9%) 0.412
CSA 3/23 (13.0%) 1/69 (1.4%) 0.077 0/10 (0%) 4/87 (4.6%) 1.000
  1. AZA azathioprine, MMF mycophenolate mofetil, MTX methotrexate, LEF leflunomide, CTX cyclophosphamide, CsA cyclosporin A